Hepatitis C Drug Raises Cure Rate in a Late Trial - NYTimes.com: "An experimental drug for hepatitis C from Vertex Pharmaceuticals sharply increased the cure rate in a clinical trial, while reducing the time needed for treatment.
Experts say the results could herald a new era in treating a sometimes fatal disease that is often overlooked, despite afflicting as many as 3.9 million Americans and 170 million people worldwide.
About 75 percent of patients in the trial who got the standard dose of Vertex’s drug in combination with the existing treatment were essentially cured, compared with 44 percent of those who got only the existing therapy."
0 comments:
Post a Comment